Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-22

Clinical Trial Update: A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial in children and adolescents with birch pollen-induced rhinoconjunctivitis completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GRAZAX (birch pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergy | Phase 3 | Status: COMPLETED | Results posted: 2025-01-22